Sanofi (SNYNF) Fair Value & Analysis
Healthcare · US · Market cap $99.8B
Sanofi
SNYNF · US
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 11 days ago
Share price +0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $79.55 – $102.06 · fair‑value band $97.69 – $203.82 · the $83.39 price screens below the $152.23 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sanofi (SNYNF) currently trades at $83.39, while our model-based Fair Value estimate is $152.23 — implying the stock looks roughly 82.6% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Sanofi generated revenue of $47.4B at a net margin of 16.0%. Revenue grew 6.0% year over year. It earns a return on equity of 6.6%. Net debt stands at $12.9B. Fundamentals as of Jun 24, 2026
Our scenario range runs from $97.69 (bear case) to $203.82 (bull case); at $83.39, the current price sits below that range. The share trades about 17% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside — at 83%, SNYNF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sanofi reported revenue of $43.6B in FY2025 versus $39.2B in FY2021, a compound +2.7%/yr. Reported net income was $7.8B in FY2025, compounding +5.8%/yr from FY2021.
Is SNYNF fairly valued? → Check now
Recent news
- Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why
- BofA Expects Positive Investor Reaction to Leadership Update at Sanofi (SNY)
- Sanofi Faces EU Probe With Fines Possibly Reaching 10%
- Sanofi Faces EU Antitrust Probe Over Flu Vaccine Communication Campaign
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
| Novartis AG N1VS34 | R$76.88 | R$56.26 | -27% |
| Novo Nordisk A/S, NOVOB | kr 307.75 | kr 542.67 | +76% |
| Amgen Inc AMGN | 6,170 MXN | 4,201 MXN | -32% |
| Gilead Sciences, Inc GIS | €115.42 | €71.19 | -38% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sanofi (SNYNF) undervalued?
What is the fair value of SNYNF?
What is the quality score of SNYNF?
What is the revenue of Sanofi (SNYNF)?
What is the net profit margin of SNYNF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.